IP Library Granted Patent US 8,771,252
Granted Patent B2
US 8,771,252 · App. 11/133,925 · Granted Jul 8, 2014

Methods and devices for renal nerve blocking

Inventors: Mark Gelfand (New York, NY); Howard R. Levin (Teaneck, NJ)
Assignee: Medtronic Ardian Luxembourg S.a.r.l.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,771,252
App. No.
11/133,925
Granted
Jul 8, 2014
Kind
B2
Abstract

A method and apparatus for treatment of cardiac and renal diseases associated with the elevated sympathetic renal nerve activity by implanting a device to block the renal nerve signals to and from the kidney. The device can be a drug pump or a drug eluting implant for targeted delivery of a nerve-blocking agent to the periarterial space of the renal artery.

Claims (17)

1. A method of treating a patient diagnosed with at least one of heart failure, hypertension, acute myocardial infarction, renal disease, or chronic renal failure, the method comprising:

delivering a neuromodulatory agent to a nerve that innervates a kidney of the patient; and

at least partially blocking neural activity along the nerve with the neuromodulatory agent and modulating at least one of urine production, blood pressure, fluid retention, renin secretion, renal blood flow, waste excretion, and sodium retention in the patient,

wherein delivering a neuromodulatory agent to a nerve that innervates a kidney of the patient comprises delivering the neuromodulatory agent via an intravascular to extravascular approach.

2. The method of claim 1 wherein delivering a neuromodulatory agent to a nerve that innervates a kidney of the patient comprises delivering at least one of an anesthetic, neurotoxin, alcohol, phenol, ketamine, and antidepressant to the nerve.

3. The method of claim 1 wherein delivering a neuromodulatory agent to a nerve that innervates a kidney of the patient comprises delivering a neuromodulatory agent via a catheter.

4. The method of claim 3 wherein a distal portion of the catheter comprises at least two electrodes, and wherein the method further comprises sensing neural activity via the electrodes.

5. The method of claim 3 wherein a distal portion of the catheter comprises at least two electrodes, and wherein the method further comprises electrically stimulating a renal nerve of the patient via the electrodes.

6. The method of claim 5 wherein the distal portion of the catheter comprises a first electrode configured to be located proximally of a nerve modulating site and a second electrode configured to be located distally of the nerve modulating site, and wherein the method further comprises sensing neural activity via the first and second electrodes.

7. The method of claim 5 wherein the distal portion of the catheter comprises a first electrode configured to be located proximally of a nerve modulating site and a second electrode configured to be located distally of the nerve modulating site, and wherein the method further comprises electrically stimulating a renal nerve of the patient with the electrodes.

8. The method of claim 1 , further comprising determining whether neural activity has been sufficiently altered.

9. The method of claim 1 wherein at least partially blocking the neural activity comprises at least substantially blocking sympathetic neural activity along a renal nerve of the patient.

10. The method of claim 9 , further comprising determining whether neural activity along the renal nerve has been substantially blocked.

11. The method of claim 10 wherein determining whether neural activity has been substantially blocked comprises electrically stimulating the renal nerve and detecting a response in the patient.

12. The method of claim 1 wherein delivering a neuromodulatory agent to a nerve that innervates a kidney of the patient comprises delivering a neuromodulatory agent via a drug delivery device.

13. The method of claim 1 wherein delivering a neuromodulatory agent to a nerve that innervates a kidney of the patient comprises positioning a needle within a periarterial space of the patient and injecting the neuromodulatory agent via the needle into the periarterial space of the patient.

14. The method of claim 13 wherein positioning a needle proximate the periarterial space of the patient comprises positioning the needle under CT guidance.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2013
From: MEDTRONIC ARDIAN LLC
To: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
Reel/Frame 030531/0717 →
CHANGE OF NAME Recorded Jun 3, 2013
From: ARDIAN, INC.
To: MEDTRONIC ARDIAN LLC
Reel/Frame 030531/0816 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2010
From: G&L CONSULTING, LLC
To: FOUNDRY NEWCO 8, INC.
Reel/Frame 024611/0120 →
CHANGE OF NAME Recorded Jun 29, 2010
From: FOUNDRY NEWCO 8, INC.
To: ARDIAN, INC.
Reel/Frame 024611/0132 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2010
From: GELFAND, MARK; LEVIN, HOWARD R.
To: G&L CONSULTING, LLC
Reel/Frame 024612/0796 →
Continuity (6)
Continuation 10900199 · Jul 28, 2004
Continuation In Part 10408665 · Apr 8, 2003
Provisional Application 60370190 · Apr 8, 2002
Provisional Application 60415575 · Oct 3, 2002
Provisional Application 60442970 · Jan 29, 2003
Related Publication 20060025821A1 · Feb 2, 2006